Aquagenic Pruritus in Myeloproliferative Neoplasms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

170 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-09

Study Completion Date

2021-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.

Prospective work based on the distribution of a dedicated questionnaire.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)

NCT06715267

Myeloproliferative Neoplasm

RECRUITING

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

NCT06361641

Myeloproliferative Neoplasm Polycythemia Vera Essential Thrombocythemia +1 more

RECRUITING NA

Myeloproliferative Neoplasms: an In-depth Case-control Study

NCT01831635

Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis

COMPLETED

Clinical Significance of Leukocyte Cell Population Data in Patients with Myeloproliferative Neoplasms (MPNs)

NCT06753279

Myeloproliferative Neoplasms (MPNs)

NOT_YET_RECRUITING

Longitudinal Data Registry of Plasma Cell Dyscrasia

NCT06760052

Multiple Myeloma and Other Plasma Cell Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis.

Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus.

Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
* Suffering (or having suffered) from aquagenic pruritus.
* No age limit, but major
* Patient having formulated his non-opposition

Exclusion Criteria

* Patients with MPN with non-aquagenic pruritus,
* Patients with another hematologic disease and aquagenic pruritus
* Patients unable to complete the questionnaire.
* Patients with physical or mental disabilities to formulate non-opposition
* Refusal of participation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No